Bayhep B market set for growth on hepatitis B demand and aging population

The Business Research Company says the Bayhep B market will keep expanding through 2026, driven by higher hepatitis B prevalence, more liver transplant activity, and broader use of post-exposure prophylaxis. North America led the market in 2025, while Asia-Pacific is expected to grow fastest as healthcare access improves and hepatitis cases rise.

Why it matters: - Bayhep B demand tracks the global hepatitis B burden, making the market a proxy for prevention and transplant-support needs. - Growth in treatment access, screening, and public health programs could expand use of hepatitis B immune globulin in hospitals and post-exposure care. - An aging population and more liver transplant procedures add to the need for prophylaxis and reinfection prevention.

What happened: - The Business Research Company released its Bayhep B Market Outlook 2030: Size, Growth Rate, Trends, and Forecast Analysis Global Market Report 2026 on November 2, 2026. - The report says the Bayhep B market has grown in past years because of high global hepatitis B prevalence. - The report forecasts continued expansion through the forecast period, driven by more liver transplants, more hepatitis screening, broader antiviral combination therapy use, better healthcare access, and government hepatitis-elimination programs. - North America held the largest share of the Bayhep B market in 2025. - Asia-Pacific is projected to be the fastest-growing regional market during the forecast period.

The details: - Bayhep B is a hepatitis B immune globulin derived from plasma. - The product contains human IgG antibodies that target hepatitis B surface antigen, or HBsAg. - Bayhep B is used to prevent hepatitis B after exposure and to reduce reinfection risk in liver-transplant patients with hepatitis B-related liver failure. - The report highlights rising use of hepatitis B immune globulin, expanded post-exposure prophylaxis, enhanced liver transplant support therapies, stronger viral hepatitis prevention efforts, and more hospital-based immunotherapy. - The report cites growing hepatitis B prevalence as a primary market driver. - The CDC reported 17,650 new chronic hepatitis B cases across 44 U.S. states and the District of Columbia in 2023, equal to a prevalence rate of 6.1 per 100,000 people. - The report links higher hepatitis B case counts to inadequate vaccination coverage, more transmission among high-risk groups, and COVID-19-related disruptions to testing and prevention. - The report also points to the expanding elderly population as a demand driver. - In the UK, 12.7 million people were aged 65 or older in 2022, or 19% of the population. - The UK Office for National Statistics projects that number will rise to 22.1 million, or 27% of the population, by 2072. - Rising healthcare spending is another support for market growth because it improves access to advanced biologics and hepatitis B immunoglobulin treatments. - UK healthcare expenditure increased 5.6% in nominal terms in 2023, a 0.9 percentage point increase from the previous year, according to the Office for National Statistics. - The market analysis covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. - The report says its 2026 editions include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel dashboards, market hotspots infographics, and technology and future-trend analysis. - The company offers a free sample of the report here and the full report here.

Between the lines: - The report frames Bayhep B as a niche but essential biologic tied to prevention infrastructure, not just treatment volume. - The strongest demand signals come from public health pressure points: chronic infection rates, transplant care, and aging populations. - Regional leadership appears to reflect healthcare system maturity, while faster growth in Asia-Pacific suggests more room for diagnosis and treatment access to expand.

What's next: - The report expects demand to rise as governments expand hepatitis elimination efforts and hospitals use more prophylaxis and immunotherapy. - Market growth will likely depend on screening rates, transplant volumes, and access to biologic therapies in emerging markets. - The Business Research Company says future reports will continue adding strategic tools and updated regional analysis.